This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
The cost of large numbers of hypothesis tests on power, effect size and sample size
Molecular Psychiatry Open Access 09 November 2010
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Heston, L.L in The Genetic Basis of Common Diseases (eds King, R.A. et al.) 792–800 (Oxford University Press, New York, 1992).
Blacker, D. et al. Nature Genet. 19, 357–360 (1998).
Tysoe, C. et al. Dement. Geriatr. Cogn. Disord. 9, 191–198 (1998).
The Medical Research Council Cognitive Function and Ageing Study Psychol. Med. 28, 319–335 (1998).
Breslow, N.E. & Day, N.E. Statistical methods in Core Research: The Design and Analysis of Case-Control Studies (Iarc Scientific Publications, Lyon, 1980).
Acknowledgements
We thank E. Buckridge and R.A. Furlong for technical and statistical assistance, the Anglia and Oxford Regional Health Authority, The Medical Research Council and The Department of Health for funding. D.C.R. is a Glaxo Wellcome Research Fellow.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Dow, D., Lindsey, N., Cairns, N. et al. α-2 macroglobulin polymorphism and Alzheimer disease risk in the UK. Nat Genet 22, 16–17 (1999). https://doi.org/10.1038/8724
Issue Date:
DOI: https://doi.org/10.1038/8724
This article is cited by
-
Influence of Alpha-2-Macroglobulin 5 bp I/D and Ile1000Val Polymorphisms on the Susceptibility of Alzheimer’s disease: A Systematic Review and Meta-analysis of 52 Studies
Cell Biochemistry and Biophysics (2014)
-
The cost of large numbers of hypothesis tests on power, effect size and sample size
Molecular Psychiatry (2012)
-
Clearance mechanisms of Alzheimer's amyloid-β peptide: implications for therapeutic design and diagnostic tests
Molecular Psychiatry (2009)
-
Ethical perspectives on pharmacogenomic profiling in the drug development process
Nature Reviews Drug Discovery (2002)
-
The genetics of Alzheimer’s disease
Current Psychiatry Reports (2000)